Welcome to HCV Advocate’s hepatitis blog. The intent of this blog is to keep our website audience up-to-date on information about hepatitis and to answer some of our web site and training audience questions. People are encouraged to submit questions and post comments.

For more information on how to use this blog
click here, the HCV drug pipeline click here, and for more information on HCV clinical trials click here

Be sure to check out our other blogs: The HBV Advocate Blog and Hepatitis & Tattoos.

Alan Franciscus
Editor-in-Chief
HCV Advocate
HBV Advocate

Friday, February 8, 2013

French biotech rapidly stuck on losing side of hep C revolution

With all-oral, interferon-free HCV regimens becoming treatment of choice, Transgene lacks partner for its therapeutic vaccine; company changes focus to HBV


By Ryan McBride for Fierce Biotech

February 8, 2013 - Fierce Biotech - Transgene CEO Philippe Archinard sees no immediate partnership in store for the hep C candidate, TG4040, and is now holding out hope that the therapeutic vaccine could find work in markets such as China where the adoption of new pills for the disease might be slower than major markets in the West, he told Bloomberg. And his company, backed by the wealthy Merieux family, has shifted focus to an experimental vaccine for hepatitis B.

Transgene has developed the hep C vaccine for use with the standard injected therapy interferon, which causes flu-like symptoms that have kept many patients on the sidelines waiting for the new all-oral regimens that work quickly and could reduce adverse side effects. The field of interferon-free contenders moved quickly in a race to bring cures to the market, which is expected to explode with the expected arrival of the pills over the next several years.

Read more...

No comments:

Post a Comment